Overview

Study of GNS561 in Patients With Liver Cancer

Status:
Recruiting

Trial end date:
2022-01-15

Target enrollment:

Participant gender:

Summary

This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genoscience Pharma